Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152617 | 0.91 | PKM (0.41) | HRH3TLR8ADORA2APKMADORA2B | |
| SCHEMBL5148981 | 0.89 | ADORA2A (0.40) | HRH3ADORA2APKMHSD17B10ADORA2B | |
| SCHEMBL5149124 | 0.88 | PKM (0.41) | HRH3ADORA2APKMADORA2BADORA1 | |
| SCHEMBL5149212 | 0.87 | SRC (0.40) | HRH3TLR8TLR7 | |
| SCHEMBL5152669 | 0.86 | PKM (0.51) | ADORA2APKMHSD17B10ADORA2BADORA1 | |
| SCHEMBL5150911 | 0.83 | MEN1 (0.49) | HRH3ADORA2AADORA2BADORA1 | |
| SCHEMBL5150924 | 0.81 | ADORA2A (0.41) | ADORA2APKMHSD17B10ADORA2BADORA1 | |
| SCHEMBL5147984 | 0.80 | BRD4 (0.43) | ADORA2APKMHSD17B10ADORA2BADORA1 | |
| SCHEMBL5149018 | 0.80 | TLR8 (0.46) | TLR8HSD17B10TLR7 | |
| SCHEMBL5152718 | 0.80 | ADORA2A (0.43) | ADORA2AHSD17B10ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| CN-1938296-A | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists | ASTELLAS PHARMA INC (JP) | 2007-03-28 | — | — | CN | disclosed |
| EP-1737841-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS | Astellas Pharma Inc. (JP) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005095384-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | HRH3 43/4885TLR8 4659/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.